TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01888874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules.
Study: NCT02039076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Study: NCT02858570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenCC-BIO Vaccine
Description: The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined - CRM197
Description: The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
Study: NCT03063684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional / Pixel CO2 Laser
Description: The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional / Pixel CO2 Laser
Description: The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application.
Study: NCT02001558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcyn
Description: Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile saline
Description: Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
Study: NCT04687163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of 130 mg/m² Oxaliplatin, and 5-fu
Description: Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of 85 mg/m² Oxaliplatin, and 5-fu
Description: Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
Study: NCT04128007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast foam 0.3%
Description: experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: experimental
Study: NCT03156166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
Study: NCT04394754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyPort
Description: Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noom
Description: Patients will receive a subscription to use Noom, a personalized diet and weight management application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversa
Description: patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
Study: NCT02066675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
Study: NCT03785236

Intervention type: RADIATION
Intervention: 68Ga-NODAGA-exendin PET/CT
Description: 68Ga-NODAGA-exendin PET/CT

Intervention type: RADIATION
Intervention: 68Ga-NODAGA-exendin PET/CT
Description: 68Ga-NODAGA-exendin PET/CT
Study: NCT04251611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance of physical exercise
Description: Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
Study: NCT01215448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheatgrass juice
Description: 110 CC daily od frozen wheatgrass juice in the intervention arm
Study: NCT03491436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iHealth Align
Description: remote monitor glucometer
Study: NCT01425905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Blues Program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hey Durham
Study: NCT04367480

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Wear placebo TENS device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Wear active TENS device
Study: NCT01833377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caraway sample

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT02856516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost Glucose Control (A)
Description: Oral nutrition supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost Glucose Control (B)
Description: Oral nutrition supplement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Boost Original
Description: Oral nutrition supplement
Study: NCT02349997

Intervention type: OTHER
Intervention: no interventions
Description: This is an observational study and no intervention applied.

Intervention type: OTHER
Intervention: no interventions
Description: This is an observational study and no intervention applied.
Study: NCT00641680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03651557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL High-dose group
Description: 1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL Low-dose group
Description: 1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
Study: NCT00863512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Standard care
Study: NCT05496153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive posture-balance cardiac rehabilitation exercise
Description: The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
Study: NCT02616159

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal
Study: NCT00005977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study: NCT02081014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection
Study: NCT03848897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metrology of motor behavior
Description: Biomechanical, physiological, psychological and behavioral analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metrology of motor behavior
Description: Biomechanical, physiological, psychological and behavioral analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metrology of motor behavior
Description: Biomechanical, physiological, psychological and behavioral analyses
Study: NCT00935077

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PPCM Asthma
Description: Pharmacists collaborate with physicians to manage asthma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 Month PPCM BP
Description: Pharmacists collaborate with physicians for 24 months to manage hypertension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 9 Month PPCM BP
Description: Pharmacists collaborate with pharmacists for 9 months to manage hypertension
Study: NCT06454643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin and gentamicin
Description: This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin and ceftriaxone
Description: Control group
Study: NCT04769492

Intervention type: OTHER
Group type: OTHER
Intervention: #ChopViolence/#ChopHIV
Description: Tailored, community-based violence prevention intervention
Study: NCT02190123

Intervention type: DRUG
Intervention: ACS patients treated with OAP
Description: Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
Study: NCT00084877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00005977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03959488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: Anti-RSV monoclonal antibody with an extended half-life

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: Approved anti-RSV monoclonal antibody
Study: NCT01026818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered by mouth for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered by mouth for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by mouth, daily or on demand for 9 months
Study: NCT02834832

Intervention type: DEVICE
Intervention: PECVD coating
Description: SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
Study: NCT03088228

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid collection
Study: NCT02773420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HET Application
Description: The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
Study: NCT00005977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT00921635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Blood transfusion to maintain hemoglobin level above 120 g/L

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion to maintain hemoglobin level above 100 g/L
Study: NCT04211558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod
Study: NCT00320697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion + nicotine patch + nicotine gum or lozenges
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: bupropion + nicotine patch + nicotine gum or lozenges
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill + placebo patch
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
Study: NCT00575471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone HCl
Description: 0.5 mg tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.0 mg tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.5 mg tablets once daily for 12 weeks
Study: NCT00005977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT00575471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily for 12 weeks
Study: NCT00077155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Study: NCT04595929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staging laparoscopy
Description: All patients undergo staging laparoscopy and peritoneal lavage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staging laparoscopy
Description: All patients undergo staging laparoscopy and peritoneal lavage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: Radical gastrectomy with D2 - lymph node dissection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical gastrectomy with D2 - lymph node dissection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².